ABG
TARS icon

Ally Bridge Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Ally Bridge Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80,859
Closed -$5.67M – 38
2026
Q1 		$5.67M Buy
+80,859
New +$5.65M 4.58% 7
2025
Q4 		– Sell
-70,778
Closed -$4.21M – 30
2025
Q3 		$4.21M Sell
70,778
-50,404
-42% -$2.48M 2.56% 17
2025
Q2 		$4.91M Sell
121,182
-6,750
-5% -$304K 4.08% 9
2025
Q1 		$6.57M Sell
127,932
-45,212
-26% -$2.23M 5.92% 5
2024
Q4 		$9.59M Sell
173,144
-148,754
-46% -$6.76M 8.22% 2
2024
Q3 		$10.6M Buy
+321,898
New +$9.05M 5.67% 2

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ally Bridge Group's TARS Position: Q2 2026 in Review

Ally Bridge Group sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 80,859 shares — an estimated $5.67M sold.

Ally Bridge Group first reported a position in TARS in Q3 2024 and held it in 6 quarters. The position peaked at $10.6M in Q3 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Ally Bridge Group reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ally Bridge Group sold 80,859 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $5.67M.
  • Ally Bridge Group first reported a position in Tarsus Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Ally Bridge Group's Tarsus Pharmaceuticals position peaked at $10.6M in Q3 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.